In vitro activity effects of twelve antibiotics alone and in association against twenty-seven enterococcus faecalis strains isolated from italian patients with infective endocarditis: High in vitro synergistic effect of the association ceftriaxone-fosfomycin

Chemotherapy

Volumn 57, Issue 5, 2012, Pages 426-433

  Farina, C ^a   Russello, G ^a   Chinello, P ^b   Pasticci, M B ^c   Raglio, A ^d   Ravasio, V ^e   Rizzi, M ^e   Scarparo, C ^f   Vailati, F ^d   Suter, F ^e  

^a AO 'Ospedale San Carlo Borromeo'   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d AO 'Ospedali Riuniti di Bergamo'   (Italy)

^e USC Malattie Infettive   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antibiotic susceptibility; Enterococcus faecalis; Fosfomycin; Synergy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FOSFOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; SHEEP;

EID: 82055178501     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000330458     Document Type: Article

References (38)

1. Anonymous: Special communication National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996: A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996; 24: 380-388.
2. Ravasio V, Rizzi M, Stellini R, Spoladore G, Durante-Mangoni E, Tripodi MF, Barbaro F, Petrosillo N, Venditti N, Crapis M, Suter F, Utili R: Current trends in infective endocarditis in Italy: report on 852 cases from the multicenter, prospective SEI study. Int J An-timicrob Agents 2009; 33:S8.
3. Fernández-Guerrero ML, Herrero L, Bellver M, Gadea I, Roblas RF, de Górgolas M: Nos-ocomial enterococcal endocarditis: a serious hazard for hospitalized patients with entero-coccal bacteraemia. J Intern Med 2002; 252: 510-515. (Pubitemid 35454327)
4. Wisplinghoff H, Bischoff T, Tallent SM, Sei-fert H, Wenzel RP, Edmond MB: Nosocomi-al bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317. (Pubitemid 39050477)
5. Elliot TSJ, Foweraker J, Gould FK, Perry JD, Sandoe JAT: Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-981. (Pubitemid 40136728)
6. Eliopoulus GM: Enterococcal endocarditis; in Kaye D (ed): Infective Endocarditis. New York, Raven Press, 1992, pp 209-229.
7. Gutschik E: New developments in the treatment of infective endocarditis and infective cardiovasculitis. Int J Antimicrob Agents 1999; 13: 79-83.
8. Ryge TS, Frimodt-Møller N, Hansen PR: Antimicrobial activities of twenty lysine-pep-toid hybrids against clinically relevant bacteria and fungi. Chemotherapy 2008; 54: 152-156. (Pubitemid 351448603)
9. Sparo MD, Jones DG, Sánchez-Bruni: Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment. Chemotherapy 2009; 55: 270-277.
10. Mueller-Premru M, Zidar N, Cvikovic Špik V, Krope A: Benzoxazine series of hystidine kinase inhibitors as potential antimicrobial agents with activity against Enterococci. Chemotherapy 2009; 55: 414-417.
11. Clinical and Laboratory Standard Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. M100-S20. Philadelphia, Villanova, 2010.
12. Pankey GA, Ashcraft DS: In vitro synergy of ciprofloxacin and gatifloxacin against cipro-floxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 2959-2964. (Pubitemid 40917617)
13. Bolmström A, Arvidson S, Ericsson M, Karlsson Å: A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (abstract No 1209). 28th Intersci Conf Antimicrob Agents Che-mother, American Society for Microbiology, Washington, 1988.
14. Chabbert YA: Simplified technic for studying bactericidal action of combined antibiotics. Ann Inst Pasteur (Paris) 1953; 85: 122-125.
15. Bonapace CR, White RL, Friedrich LV, Bosso JA: Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000; 38: 43-50.
16. Pankey GA, Ashcraft DS: The detection of synergy between meropenem and polymyx-in B against meropenem-resistant Acineto-bacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 2009; 63: 228-232.
17. Manno G, Ugonotti E, Belli M, Fenu ML, Romano L, Cruciani M: Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2003; 22: 28-34. (Pubitemid 36286690)
18. Miro JM, Cervera C, Garcia-de-la-Maria C, et al: Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity. Scand J Infect Dis 2008; 40: 968-972.
19. Euba G, Lora-Tamayo J, Murillo O, et al: Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009; 53: 4305-4310.
20. Gavalda J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, Almirante B, Ru i z F, Borrel l N, Gom i s X, Pig rau C, Baque-ro F, Pahissa A: Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43: 639-648.
21. Gavalda J, Len O, Miro JM, Almirante B, Pa-hissa A: Brief communication: treatment of Enterococcus faecalis endocarditis with am-picillin plus ceftriaxone. Ann Intern Med 2007; 146: 574-579. (Pubitemid 351650538)
22. Mainardi JL, Gutmann L, Acar JF, Goldstein FW: Synergistic effect of amoxicillin and ce-fotaxime against Enterococcus faecalis. Anti-microb Agents Chemother 1995; 39: 1984-1987.
23. Singh A: Ampicillin plus ceftriaxone for high-level aminoglycoside- resistant Entero-coccus faecalis endoca rditis. Ann Intern Med 2007; 14 6: 574-579.
24. Pasticci MB, Mencaccia A, Moretti A, Pal-ladino N, Lapalorcia LM, Bistoni F, Baldelli F: In vitro antimicrobial activity of ampicil-lin-ceftriaxone and ampicillin-ertapenem combinations against clinical isolates of En-terococcus faecalis w it h hig h level s of a mino-glycoside resistance. Open Microbiol J 2008; 2: 79-84.
25. Baddour LM, Wilson WR, Bayer AS Jr, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pal-lasch TJ, Takahashi M, Taubert KA: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association Executive. endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: 3167-3184. (Pubitemid 40851995)
26. Heather H, Houlihan C, Daniela P, Rybak MJ: Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. J Antimicrob Chemother 2000; 46: 79-86. (Pubitemid 30466200)
27. Fass RJ, Wright CA: Comparative efficacies of mezlocillin and ampicillin alone or in combination with gentamicin in the treatment of Streptococcus faecalis endocarditis in rabbits. Antimicrob Agents Chemother 1984; 25: 408-410. (Pubitemid 14129592)
28. Sweeney MT, Zurenko GE: In vitro activities of linezolid with other antimicrobial agents against Staphylococci, Enterococci, Pneu-mococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47: 1902-1906. (Pubitemid 36637812)
29. Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V, Kergueris MF, Bugnon D, Potel G, Caillon J: In vitro and in vivo syn-ergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 45-51. (Pubitemid 40065771)
30. Berdal JE, Eskesen A: Short-term success, but long-term treatment failure with linezol-id for enterococcal endocarditis. Scand J Infect Dis 2008; 40: 765-766.
31. Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM: Vancomycin-resistant En-terococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 2007; 45: 631-635.
32. Debbia E, Varaldo PE, Schito GC: In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampicin. Antimicrob Agents Chemother 1986; 30: 813-815. (Pubitemid 17187724)
33. Cha R, Brown WJ, Rybak MJ: Bactericidal activities of daptomycin, quinupristin-dal-fopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47: 3960-3963. (Pubitemid 37485015)
34. Fuchs PC, Barry AL, Brown SD: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49: 467-470. (Pubitemid 34223667)
35. Le J, Rudisill CN, Hashern MG, Iqbal R, James CL, Sakoulas G: Treatment of menin-g it i s caus e d by v a nc omyc i n-re s i s t a nt Entero-coccus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother 2010; 44: 2001-2006.
36. Roveta S, Marchese A, Debbia EA: Tigecy-cline in vitro activity against Gram-negative and Gram-positive pathogens collected in Italy. Chemotherapy 2008; 54: 43-49. (Pubitemid 350308284)
37. Entenza JM, Moreillon P: Tigecycline in combination with other antimicrobials: a rev iew of i n v itro, a n i ma l a nd ca se re por t st ud-ies. Int J Antimicrob Agents 2009; 34: 8.e1-e9.
38. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME: Synergy of fos-fomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359-368.